-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Structure Therapeutics, Raises Price Target to $120

Benzinga·12/12/2025 12:55:31
Listen to the news
Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and raises the price target from $87 to $120.